Amyloid-Targeted Strategies in Alzheimer Disease Management

(6:7)

Targeting β-amyloid and tau in Alzheimer's disease

(3:11)

Future Investigation and Use of Amyloid-Targeted Agents in AD

(3:53)

Cardiac amyloidosis 101: Why early diagnosis and targeted treatment matter

(51)

The AD pipeline and role of amyloid-beta

(5:59)

Alzheimer's Disease - Amyloidopathy

(32:48)

Costantino Iadecola, MD: The Impact of Amyloid on Vascular Dysfunction

(5:20)

Innate and vaccine-generated antibodies against transthyretin amyloid - Brian O'Nuallain

(23:8)

Is amyloid lowering still a valid approach in Alzheimer’s disease?

(2:24)

Targeting deposits in amyloidosis

(49)

A New Standard of Alzheimer's Care: The New Era of Amyloid-Targeting Therapies

(59:27)

Development of a new anti-amyloid antibody PMN310 for the treatment of Alzheimer’s disease

(2:38)

Second generation of anti-amyloid monoclonal antibodies for Alzheimer's disease

(1:28)

Enhancing safety and efficacy in amyloid-targeted therapies

(19:39)

A New Standard of Alzheimer's Care: The New Era of Amyloid-Targeting Therapies

(48:8)

Targeting amyloid beta production for Alzheimer's disease

(1:42:34)

Identifying and targeting unconventional druggable sites on pathological amyloid fibrils

(58:8)

Alzheimer's Disease - The amyloid cascade, alternative mechanisms

(29:25)

The ALTITUDE-AD trial: targeting soluble amyloid-β oligomers with sabirnetug in AD

(1:43)